Scarica l'app Stockscreener
1.955
0.61%
0.005
Precedente Chiudi:
$1.95
Aprire:
$1.95
Volume 24 ore:
2.13M
Relative Volume:
0.30
Capitalizzazione di mercato:
$404.86M
Reddito:
$176.23M
Utile/perdita netta:
$-257.83M
Rapporto P/E:
-1.3483
EPS:
-1.45
Flusso di cassa netto:
$-246.00M
1 W Prestazione:
-8.75%
1M Prestazione:
+114.88%
6M Prestazione:
+228.41%
1 anno Prestazione:
+424.85%
Intervallo 1D:
$1.89
$2.03
Intervallo di 1 settimana:
$1.82
$2.185
Portata 52W:
$0.304
$3.179
Sangamo Therapeutics Inc Stock (SGMO) Company Profile
Nome
Sangamo Therapeutics Inc
Settore
Industria
Telefono
(510) 970-6000
Indirizzo
501 CANAL BLVD., RICHMOND, CA
Confronta SGMO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| SGMO | 1.96 | 404.86M | 176.23M | -257.83M | -246.00M | -1.45 |
| VRTX | 450.00 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 748.66 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 588.46 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.13 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 106.50 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-04-28 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-02-27 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2023-01-06 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-06-13 | Ripresa | Wedbush | Neutral |
| 2021-05-04 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-01-07 | Ripresa | Guggenheim | Neutral |
| 2021-01-06 | Iniziato | Stifel | Hold |
| 2020-12-16 | Ripresa | H.C. Wainwright | Buy |
| 2020-09-08 | Iniziato | BofA Securities | Buy |
| 2020-07-07 | Iniziato | SunTrust | Buy |
| 2019-08-26 | Iniziato | H.C. Wainwright | Buy |
| 2018-11-14 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-11-09 | Downgrade | Guggenheim | Buy → Neutral |
| 2018-10-10 | Iniziato | Guggenheim | Buy |
| 2018-06-20 | Iniziato | BofA/Merrill | Buy |
| 2017-11-15 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2017-06-22 | Ripresa | Jefferies | Buy |
| 2016-11-01 | Downgrade | Wedbush | Outperform → Neutral |
| 2016-10-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2015-12-04 | Iniziato | Wells Fargo | Outperform |
| 2015-10-23 | Ripresa | Jefferies | Buy |
| 2013-05-03 | Iniziato | BioLogic Equity Research | Sell |
| 2011-02-23 | Reiterato | JMP Securities | Mkt Outperform |
| 2010-07-29 | Reiterato | Wedbush | Outperform |
| 2009-10-19 | Iniziato | Brean Murray | Sell |
| 2009-10-07 | Reiterato | Leerink Swann | Outperform |
| 2009-08-25 | Reiterato | JMP Securities | Mkt Outperform |
Mostra tutto
Sangamo Therapeutics Inc Borsa (SGMO) Ultime notizie
Analysts Just Made A Massive Upgrade To Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Forecasts - Simply Wall St
Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain - BioSpace
Sangamo stock climbs 12% post-market on FDA update for ST-503 - MSN
Sangamo Therapeutics Gets FDA Clearance for Investigational NDA for Pain Treatment - Marketscreener.com
Sangamo's Novel Gene Therapy for Chronic Pain Gets FDA Clearance for Clinical Trials | SGMO Stock News - StockTitan
What is HC Wainwright's Forecast for SGMO FY2024 Earnings? - MarketBeat
FY2028 Earnings Forecast for SGMO Issued By HC Wainwright - MarketBeat
Sangamo Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St
Sangamo Therapeutics (NASDAQ:SGMO) Price Target Raised to $9.00 at Barclays - MarketBeat
Sangamo Therapeutics' SWOT analysis: gene therapy firm's stock faces challenges, opportunities - Investing.com Canada
Sangamo: Q3 Earnings Snapshot - Marketscreener.com
Sangamo Therapeutics (SGMO) Tops Q3 Earnings and Revenue Estimates - MSN
Earnings call: Sangamo Therapeutics reports progress in gene therapies By Investing.com - Investing.com Australia
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q3 2024 Earnings Call Transcript - Insider Monkey
Earnings call: Sangamo Therapeutics reports progress in gene therapies - Investing.com India
Sangamo Therapeutics Inc (SGMO) Q3 2024 Earnings Call Highlights: Strategic Advances and ... By GuruFocus - Investing.com Canada
SGMOSangamo Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Sangamo Therapeutics Inc (SGMO) Q3 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance
Sangamo Therapeutics Q3 beats propel stock 5% higher - MSN
Sangamo Therapeutics earnings beat by $0.06, revenue topped estimates - Investing.com UK
Sangamo Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results - Business Wire
Sangamo Therapeutics's Earnings Outlook - Benzinga
FY2024 Earnings Forecast for SGMO Issued By HC Wainwright - Defense World
Gene Therapy Market to Grow by USD 6.74 Billion from 2024-2028, as Rise in Special Drug Designations Drives Demand with AI-Powered Market EvolutionTechnavio - The Malaysian Reserve
Equities Analysts Set Expectations for SGMO FY2024 Earnings - MarketBeat
Sangamo Therapeutics (NASDAQ:SGMO) Reaches New 12-Month High on Analyst Upgrade - Defense World
Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences - The Manila Times
Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences - GlobeNewswire Inc.
Sangamo (SGMO) Stock Rally Continues In Pre-Market Ahead of Financial Results Release - Stocks Telegraph
Sangamo Therapeutics (SGMO) Set to Announce Quarterly Earnings on Tuesday - MarketBeat
Sangamo Therapeutics (NASDAQ:SGMO) Price Target Raised to $10.00 at HC Wainwright - MarketBeat
Vanguard Group Inc's Strategic Reduction in Sangamo Therapeutics Inc - GuruFocus.com
Sangamo Therapeutics Announces Third Quarter 2024 Conference Call and Webcast - StockTitan
individual investors who own 55% along with institutions invested in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) saw increase in their holdings value last week - Yahoo Finance
Sangamo Therapeutics (NASDAQ:SGMO) Stock Crosses Above 200 Day Moving Average – Here’s Why - Defense World
Sangamo Therapeutics (NASDAQ:SGMO) Stock Passes Above 200 Day Moving AverageWhat's Next? - MarketBeat
Gene Therapy Market Detailed Analysis and Forecast to 2031 - InsightAce Analytic
StockWatch: Sangamo Shares Surge on Shorter Pathway for Fabry Candidate - Genetic Engineering & Biotechnology News
Fabry disease gene therapy study data enough for FDA submission - Fabry Disease News
Prime Medicine Spat with Tessera Rumbles on at ESGCT - Genetic Engineering & Biotechnology News
Booz Allen Posts Upbeat Q3 Earnings, Joins Deckers Outdoor, Saia, Boyd Gaming And Other Big Stocks Moving Higher On FridayBooz Allen Hamilton (NYSE:BAH) - Benzinga
Sangamo Therapeutics' SWOT analysis: genomic medicine stock at crossroads - Investing.com
Sangamo Therapeutics' SWOT analysis: genomic medicine stock at crossroads By Investing.com - Investing.com UK
4 Analysts Have This To Say About Sangamo Therapeutics - Benzinga
What Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) 26% Share Price Gain Is Not Telling You - Simply Wall St
Sangamo shares jump as FDA clears faster gene therapy pathway - The Pharma Letter
Sangamo stock rallies 37% on FDA update for Fabry disease drug - MSN
Sangamo Therapeutics, Cyclacel Pharma, GE Aerospace: 3 Stocks Retailers Are Most Bullish Tuesday Afternoon - Barchart
Sangamo Therapeutics (NASDAQ:SGMO) Stock Rating Reaffirmed by HC Wainwright - MarketBeat
Traders Purchase Large Volume of Call Options on Sangamo Therapeutics (NASDAQ:SGMO) - MarketBeat
Sangamo Therapeutics Inc Azioni (SGMO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.80%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):